Nanocarriers-based therapeutic strategy for drug-resistant epilepsy: A systematic review

IF 5.3 2区医学 Q1 PHARMACOLOGY & PHARMACY

International Journal of Pharmaceutics Pub Date : 2024-11-22 DOI:10.1016/j.ijpharm.2024.124986

Roberto Diaz-Peregrino , Daniel San-Juan , Carlos Patiño-Ramirez , Lenin V. Sandoval-Luna , Aleida Arritola-Uriarte

{"title":"Nanocarriers-based therapeutic strategy for drug-resistant epilepsy: A systematic review","authors":"Roberto Diaz-Peregrino , Daniel San-Juan , Carlos Patiño-Ramirez , Lenin V. Sandoval-Luna , Aleida Arritola-Uriarte","doi":"10.1016/j.ijpharm.2024.124986","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Nanocarriers have been proposed as a solution for drug-resistant epilepsy.</div></div><div><h3>Methods</h3><div>A systematic review of animal and in vitro studies was conducted to evaluate the efficacy, toxicity, and biological properties of nanocarriers. Searches were performed in PubMed/Medline and Scopus from March 2023 to March 2024.</div></div><div><h3>Results</h3><div>Eighteen studies were identified: 2 in vitro, 9 <em>in vivo</em>, and 7 combined. While epilepsy models and seizure control assessments were consistent, there was variability in evaluating the potential toxicity of nanocarriers. Only one study did not show a reduction in brain inflammation, seizures, and cell loss. Nanocarrier toxicity was evaluated just in six studies, all of which indicated low toxicity both in vitro and <em>in vivo</em>.</div></div><div><h3>Conclusions</h3><div>Nanocarriers with antiseizure drugs manage seizures, inflammation, oxidative stress, and behavior impairment in drug-resistant epilepsy. Furthermore, nanocarriers are a safe option for delivering antiseizure drugs, though more research is needed to confirm these findings.</div></div>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":"668 ","pages":"Article 124986"},"PeriodicalIF":5.3000,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0378517324012201","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Nanocarriers have been proposed as a solution for drug-resistant epilepsy.

Methods

A systematic review of animal and in vitro studies was conducted to evaluate the efficacy, toxicity, and biological properties of nanocarriers. Searches were performed in PubMed/Medline and Scopus from March 2023 to March 2024.

Results

Eighteen studies were identified: 2 in vitro, 9 in vivo, and 7 combined. While epilepsy models and seizure control assessments were consistent, there was variability in evaluating the potential toxicity of nanocarriers. Only one study did not show a reduction in brain inflammation, seizures, and cell loss. Nanocarrier toxicity was evaluated just in six studies, all of which indicated low toxicity both in vitro and in vivo.

Conclusions

Nanocarriers with antiseizure drugs manage seizures, inflammation, oxidative stress, and behavior impairment in drug-resistant epilepsy. Furthermore, nanocarriers are a safe option for delivering antiseizure drugs, though more research is needed to confirm these findings.

Abstract Image

查看原文本刊更多论文

基于纳米载体的耐药性癫痫治疗策略：系统综述。

背景：纳米载体已被提出作为抗药性癫痫的一种解决方案：方法：对动物和体外研究进行了系统回顾，以评估纳米载体的疗效、毒性和生物特性。结果：共发现了 18 项研究：其中有 1 项研究发现了纳米载体的抗药性；1 项研究发现了纳米载体的毒性；1 项研究发现了纳米载体的生物特性：结果：共发现 18 项研究：结果：共发现 18 项研究：2 项体外研究、9 项体内研究和 7 项综合研究。虽然癫痫模型和癫痫控制评估是一致的，但在评估纳米载体的潜在毒性方面存在差异。只有一项研究未显示脑部炎症、癫痫发作和细胞丢失有所减少。仅有六项研究对纳米载体的毒性进行了评估，所有这些研究都表明纳米载体在体外和体内的毒性都很低：含有抗癫痫药物的纳米载体可控制耐药性癫痫的发作、炎症、氧化应激和行为障碍。此外，纳米载体是递送抗癫痫药物的安全选择，但还需要更多的研究来证实这些发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Pharmaceutics 医学-药学

CiteScore

10.70

自引率

8.60%

发文量

951

审稿时长

72 days

期刊介绍： The International Journal of Pharmaceutics is the third most cited journal in the "Pharmacy & Pharmacology" category out of 366 journals, being the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation. This includes evaluation of the properties of drugs, excipients such as surfactants and polymers and novel materials. The journal has special sections on pharmaceutical nanotechnology and personalized medicines, and publishes research papers, reviews, commentaries and letters to the editor as well as special issues.